Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

55750-53-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • USA/EU/Au/Br/Local Warehouse Direct Shipment Top Quality 6-Maleimidocaproic acid/N-MALEOYL-6-AMINO-CAPROIC ACID Best price N-(5-Carboxy-n-pentyl)MaleiMide CAS 55750-53-3

    Cas No: 55750-53-3

  • USD $ 2.0-2.0 / Gram

  • 10 Gram

  • 1000 Kilogram/Month

  • Xi'an Faithful Biotech Co., Ltd.
  • Contact Supplier

55750-53-3 Usage


6-Maleimidocaproic acid is a chemical compound that features a maleimide group and a terminal carboxylic acid. The terminal carboxylic acid is capable of reacting with primary amine groups to form stable amide bonds, while the maleimide group can form covalent bonds with thiol groups, facilitating the attachment of biomolecules with thiols.


Used in Bioconjugation:
6-Maleimidocaproic acid is used as a bifunctional cross-linking reagent for the conjugation of biomolecules with thiol groups. It is particularly useful in the formation of stable amide bonds with primary amine groups, enhancing the stability and functionality of the resulting bioconjugates.
Used in Pharmaceutical Development:
6-Maleimidocaproic acid serves as a probe for introducing maleimide groups into active pharmaceutical ingredients. This allows for the development of new drug candidates with improved properties, such as enhanced solubility, stability, or targeted delivery.
Used in Protein Modification:
In the field of protein chemistry, 6-maleimidocaproic acid is used as a probe for thiol groups in membrane proteins. This enables the modification and functionalization of proteins, which can be crucial for understanding their structure, function, and potential applications in medicine and biotechnology.
Overall, 6-maleimidocaproic acid is a versatile chemical tool with applications in bioconjugation, pharmaceutical development, and protein modification, making it an important compound in the fields of chemistry, biology, and medicine.

Check Digit Verification of cas no

The CAS Registry Mumber 55750-53-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,7,5 and 0 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 55750-53:
133 % 10 = 3
So 55750-53-3 is a valid CAS Registry Number.

55750-53-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (M2338)  6-Maleimidohexanoic Acid  >98.0%(GC)(T)

  • 55750-53-3

  • 1g

  • 790.00CNY

  • Detail
  • Alfa Aesar

  • (46384)  6-Maleimidohexanoic acid   

  • 55750-53-3

  • 5g

  • 506.0CNY

  • Detail
  • Alfa Aesar

  • (46384)  6-Maleimidohexanoic acid   

  • 55750-53-3

  • 25g

  • 1590.0CNY

  • Detail
  • Alfa Aesar

  • (46384)  6-Maleimidohexanoic acid   

  • 55750-53-3

  • 100g

  • 5086.0CNY

  • Detail
  • Aldrich

  • (755842)  6-Maleimidohexanoic acid  90% (GC)

  • 55750-53-3

  • 755842-25G

  • 1,845.09CNY

  • Detail
  • Sigma-Aldrich

  • (63176)  6-Maleimidohexanoic acid  ≥98.0% (HPLC)

  • 55750-53-3

  • 63176-1G-F

  • 4,013.10CNY

  • Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017


1.1 GHS Product identifier

Product name 6-Maleimidocaproic Acid

1.2 Other means of identification

Product number -
Other names 6-(2,5-dioxopyrrol-1-yl)hexanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55750-53-3 SDS

55750-53-3Relevant articles and documents

Photopolymerization of maleimide perfluoropolyalkylethers without a photoinitiator

Bonneaud, Céline,Burgess, Julia M.,Bongiovanni, Roberta,Joly-Duhamel, Christine,Friesen, Chadron M.

, p. 699 - 707 (2019)

Perfluoropolyalkylethers derived from hexafluoropropylene oxide were functionalized with maleimide groups. Irradiated by UV-light, the new maleimide macromonomers demonstrated very fast polymerization kinetics with a curing time as fast as 8 s. The effect on photopolymerization of different features such as the molecular weight of the fluorinated chain and the chain length of the hydrogenated spacer were studied, as well as the influence of the type of photoinitiator and the presence of air. Thermal and surface properties of the UV-cured polymers were examined and were typical to fluoropolymers in view of water–oil repellent coatings.

Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy

Zhang, Huicong,Sun, Zhisu,Wang, Kuanglei,Li, Na,Chen, Hongxiang,Tan, Xiao,Li, Lingxiao,He, Zhonggui,Sun, Jin

, p. 1852 - 1858 (2018)

We report a new type of amide bond-bearing cathepsin B-sensitive gemcitabine (GEM) prodrugs, capable of in situ covalently targeting circulating albumin and then making a hitchhike to the tumor. Specially, less plasma-enzyme deactivation, long plasma half-life, independence on nucleoside transporters, outstanding tumor targeting, and site-specific drug release are achieved, and as such these multifunctional advantages contribute to the dramatically increased in vivo antitumor efficacy.

Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery

Wei, Wei,He, Zhonggui,Yang, Jincheng,Sun, Mengchi,Sun, Jin

, p. 1162 - 1170 (2018)

Rational design of anticancer prodrugs for efficient albumin binding can show distinct advantages in drug delivery in terms of high drug availability, long systemic circulation, potential targeting effect, and enhanced chemotherapy effect. In the present study, we reported a cytosine arabinoside (Ara-C) prodrug which could well formulate in solution and instantly transform into long-circulating nanocomplexes by hitchhiking blood-circulating albumin after i.v. administration. Specifically, Ara-C was conjugated with an albumin-binding maleimide derivative, the resulting Ara-C maleimide caproic acid conjugate (AM) was well formulated in aqueous solution, conferring high albumin-binding ability in vitro albumin-binding studies. Moreover, in vivo fluorescence images of sulfo-cyanine5 maleimide indirectly demonstrated that AM showed better accumulation in tumors, exhibiting superior tumor targeting ability and antitumor activity compared to Ara-C. Such a uniquely developed strategy, integrating high albumin-binding capability, has great potential to be applied in clinical cancer therapy.

Linker, Antibody-Drug Conjugate Including Same and Use Thereof


Paragraph 0532; 0533, (2021/08/27)

Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.

A designed cyclic peptide based on Trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability

Zhou, Jiaqi,Zou, Yuxing,Cai, Yan,Chi, Fanglian,Huang, Wenlong,Shi, Wei,Qian, Hai

, (2021/11/08)

Human epidermal growth factor receptor 2 (HER2) has been recognized as an important therapeutic target for its overexpression in many cancers. Trastuzumab is a monoclonal antibody targeting HER2, which has been approved by FDA to treat HER2-positive cancer. In this research, cyclic peptide Cyclo-GCGPep1 was designed based on the binding mode between antibody and HER2 protein in silico, which has been confirmed possessing good affinity with HER2. Cyclo-GCGPep1 was also used to construct peptide-drug conjugates with Camptothecin. Biological evaluations demonstrated that Conjugate 1 has a good antiproliferative activity on SK-BR-3 and NCI-N87 cells. Conjugate 1 retained the pro-apoptotic and Topo I inhibitory ability of Camptothecin. Meanwhile, it has good targeting ability towards HER2-positive cells with the help of Cyclo-GCGPep1. It also has better permeability in the tumor spheroid model than Camptothecin. In summary, the design of cyclic peptide derived from antibody is of significance for the discovery of targeting peptides and Conjugate 1 is expected as a good therapeutic agent for HER2-positive cancers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 55750-53-3